20 Aug Date August 20, 2025 Author TelaraPharma Tags Dr. Alberto Lázaro, The Cilastatin project New paper published: Cilastatin Modulates DPEP1- and IQGAP1-Associated Neuro-Glio-Vascular Inflammation in Oxaliplatin-Induced Peripheral Neurotoxicity Martín-Ramírez R, González-Nicolás MÁ, Álvarez-Tosco K, Machín F, Ávila J, Morales M, Lázaro A, Martín-Vasallo P.Cells....
16 Aug Date August 16, 2025 Author TelaraPharma Tags Arch Biopartners, Dr. Alberto Lázaro, The Cilastatin project New paper published: Cilastatin Attenuates Acute Kidney Injury and Reduces Mortality in a Rat Model of Sepsis. https://www.mdpi.com/1422-0067/26/16/7927 González-Nicolás MÁ, Humanes B, Herrero R, Arenillas M, López B, Ferruelo A, Lore...
27 May Date May 27, 2025 Author TelaraPharma Tags Dr. Alberto Lázaro, Gregorio Marañon, The Cilastatin project Telara Pharma Earns Emerging Company Certification from Enisa Telara Pharma is proud to announce that it has been officially recognized with the Emerging Company Certification, granted by the...
23 Sep Date September 23, 2024 Author TelaraPharma Tags Dr. Alberto Lázaro, The Cilastatin project Our CSO Dr. Alberto Lázaro publishes a Commentary in the Kidney International Journal about Cilastatin Our Co-Founder and CSO Dr. Alberto Lázaro has just published a Commentary in the Kidney International Journal, the official journ...
03 Jun Date June 3, 2021 Author TelaraPharma Tags Dr. Alberto Lázaro, Gregorio Marañon, IiSGM Telara Pharma awarded at the 8th IiSGM Research and Innovation Conference Alberto Lázaro, co-founder of Telara Pharma, wins the award for Best Communication with an innovation component for the presentat...